clinical information
FAQ, Phase III Safety and Efficacy Data, Drug Facts, Mechanism of Action Video
FAQ, Phase III Safety and Efficacy Data, Drug Facts, Mechanism of Action Video
How to order, coupon tearpads, request samples, educational videos, downloadable social media posts and digital banners
A redness reliever like no other
LUMIFY (brimonidine tartrate ophthalmic solution
0.025%) is the first and only over-the-counter (OTC)
eye drop developed with low-dose brimonidine
tartrate for the treatment of ocular redness due to
minor eye irritations.
Other OTC redness relievers
(α1 or α1/α2-AR agonist)
Commonly associated with
rebound redness and tachyphylaxis
Non-selective vasoconstrictors
act on the arteriole, decreasing
blood and oxygen flow to
surrounding tissue.
VS
LUMIFY with low dose brimonidine tartrate
(Selective α2-AR agonist)
No tachyphylaxis and virtually
no rebound redness in clinical trials
when used as directed
LUMIFY selectively constricts
the venule, alleviating the potential
decrease of blood and oxygen flow
to surrounding tissue.
Real results from real people, no retouching.*